Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

George D. Demetri, Christopher R. Garrett, Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio Lopez Pousa, Axel Le Cesne, David Goldstein, Luis Paz-Ares, Jean Yves Blay, Grant A. McArthur, Qiang Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess correlative angiogenesis biomarkers with patient outcomes. Experimental Design: Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease progression/study unblinding. Overall survival (OS) was analyzed using conventional statistical methods and the rank-preserving structural failure time (RPSFT) method to explore cross-over impact. Circulating levels of angiogenesis biomarkers were analyzed. Results: In total, 243 patients were randomized to receive sunitinib and 118 to placebo, 103 of whom crossed over to open-label sunitinib. Conventional statistical analysis showed that OS converged in the sunitinib and placebo arms (median 72.7 vs. 64.9 weeks; HR, 0.876; P=0.306) as expected, given the cross-over design. RPSFT analysis estimated median OS for placebo of 39.0 weeks (HR, 0.505, 95% CI, 0.262-1.134; P = 0.306). No new safety concerns emerged with extended sunitinib treatment. No consistent associations were found between the pharmacodynamics of angiogenesis-related plasma proteins during sunitinib treatment and clinical outcome. Conclusions: The cross-over design provided evidence of sunitinib clinical benefit based on prolonged time to tumor progression during the double-blind phase of this trial. As expected, following cross-over, there was no statistical difference in OS. RPSFT analysis modeled the absence of cross-over, estimating a substantial sunitinib OS benefit relative to placebo. Long-term sunitinib treatment was tolerated without new adverse events.

Original languageEnglish
Pages (from-to)3170-3179
Number of pages10
JournalClinical Cancer Research
Volume18
Issue number11
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Gastrointestinal Stromal Tumors
Placebos
Survival
Cross-Over Studies
sunitinib
Imatinib Mesylate
Biomarkers
Disease Progression
Blood Proteins
Appointments and Schedules
Research Design
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. / Demetri, George D.; Garrett, Christopher R.; Schöffski, Patrick; Shah, Manisha H.; Verweij, Jaap; Leyvraz, Serge; Hurwitz, Herbert I.; Pousa, Antonio Lopez; Le Cesne, Axel; Goldstein, David; Paz-Ares, Luis; Blay, Jean Yves; McArthur, Grant A.; Xu, Qiang; Huang, Xin; Harmon, Charles S.; Tassell, Vanessa; Cohen, Darrel P.; Casali, Paolo G.

In: Clinical Cancer Research, Vol. 18, No. 11, 01.06.2012, p. 3170-3179.

Research output: Contribution to journalArticle

Demetri, GD, Garrett, CR, Schöffski, P, Shah, MH, Verweij, J, Leyvraz, S, Hurwitz, HI, Pousa, AL, Le Cesne, A, Goldstein, D, Paz-Ares, L, Blay, JY, McArthur, GA, Xu, Q, Huang, X, Harmon, CS, Tassell, V, Cohen, DP & Casali, PG 2012, 'Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure', Clinical Cancer Research, vol. 18, no. 11, pp. 3170-3179. https://doi.org/10.1158/1078-0432.CCR-11-3005
Demetri, George D. ; Garrett, Christopher R. ; Schöffski, Patrick ; Shah, Manisha H. ; Verweij, Jaap ; Leyvraz, Serge ; Hurwitz, Herbert I. ; Pousa, Antonio Lopez ; Le Cesne, Axel ; Goldstein, David ; Paz-Ares, Luis ; Blay, Jean Yves ; McArthur, Grant A. ; Xu, Qiang ; Huang, Xin ; Harmon, Charles S. ; Tassell, Vanessa ; Cohen, Darrel P. ; Casali, Paolo G. / Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 11. pp. 3170-3179.
@article{7ecf2e7904614cc196958abbb67c4bc6,
title = "Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure",
abstract = "Purpose: To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess correlative angiogenesis biomarkers with patient outcomes. Experimental Design: Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease progression/study unblinding. Overall survival (OS) was analyzed using conventional statistical methods and the rank-preserving structural failure time (RPSFT) method to explore cross-over impact. Circulating levels of angiogenesis biomarkers were analyzed. Results: In total, 243 patients were randomized to receive sunitinib and 118 to placebo, 103 of whom crossed over to open-label sunitinib. Conventional statistical analysis showed that OS converged in the sunitinib and placebo arms (median 72.7 vs. 64.9 weeks; HR, 0.876; P=0.306) as expected, given the cross-over design. RPSFT analysis estimated median OS for placebo of 39.0 weeks (HR, 0.505, 95{\%} CI, 0.262-1.134; P = 0.306). No new safety concerns emerged with extended sunitinib treatment. No consistent associations were found between the pharmacodynamics of angiogenesis-related plasma proteins during sunitinib treatment and clinical outcome. Conclusions: The cross-over design provided evidence of sunitinib clinical benefit based on prolonged time to tumor progression during the double-blind phase of this trial. As expected, following cross-over, there was no statistical difference in OS. RPSFT analysis modeled the absence of cross-over, estimating a substantial sunitinib OS benefit relative to placebo. Long-term sunitinib treatment was tolerated without new adverse events.",
author = "Demetri, {George D.} and Garrett, {Christopher R.} and Patrick Sch{\"o}ffski and Shah, {Manisha H.} and Jaap Verweij and Serge Leyvraz and Hurwitz, {Herbert I.} and Pousa, {Antonio Lopez} and {Le Cesne}, Axel and David Goldstein and Luis Paz-Ares and Blay, {Jean Yves} and McArthur, {Grant A.} and Qiang Xu and Xin Huang and Harmon, {Charles S.} and Vanessa Tassell and Cohen, {Darrel P.} and Casali, {Paolo G.}",
year = "2012",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-11-3005",
language = "English",
volume = "18",
pages = "3170--3179",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

AU - Demetri, George D.

AU - Garrett, Christopher R.

AU - Schöffski, Patrick

AU - Shah, Manisha H.

AU - Verweij, Jaap

AU - Leyvraz, Serge

AU - Hurwitz, Herbert I.

AU - Pousa, Antonio Lopez

AU - Le Cesne, Axel

AU - Goldstein, David

AU - Paz-Ares, Luis

AU - Blay, Jean Yves

AU - McArthur, Grant A.

AU - Xu, Qiang

AU - Huang, Xin

AU - Harmon, Charles S.

AU - Tassell, Vanessa

AU - Cohen, Darrel P.

AU - Casali, Paolo G.

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Purpose: To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess correlative angiogenesis biomarkers with patient outcomes. Experimental Design: Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease progression/study unblinding. Overall survival (OS) was analyzed using conventional statistical methods and the rank-preserving structural failure time (RPSFT) method to explore cross-over impact. Circulating levels of angiogenesis biomarkers were analyzed. Results: In total, 243 patients were randomized to receive sunitinib and 118 to placebo, 103 of whom crossed over to open-label sunitinib. Conventional statistical analysis showed that OS converged in the sunitinib and placebo arms (median 72.7 vs. 64.9 weeks; HR, 0.876; P=0.306) as expected, given the cross-over design. RPSFT analysis estimated median OS for placebo of 39.0 weeks (HR, 0.505, 95% CI, 0.262-1.134; P = 0.306). No new safety concerns emerged with extended sunitinib treatment. No consistent associations were found between the pharmacodynamics of angiogenesis-related plasma proteins during sunitinib treatment and clinical outcome. Conclusions: The cross-over design provided evidence of sunitinib clinical benefit based on prolonged time to tumor progression during the double-blind phase of this trial. As expected, following cross-over, there was no statistical difference in OS. RPSFT analysis modeled the absence of cross-over, estimating a substantial sunitinib OS benefit relative to placebo. Long-term sunitinib treatment was tolerated without new adverse events.

AB - Purpose: To analyze final long-term survival and clinical outcomes from the randomized phase III study of sunitinib in gastrointestinal stromal tumor patients after imatinib failure; to assess correlative angiogenesis biomarkers with patient outcomes. Experimental Design: Blinded sunitinib or placebo was given daily on a 4-week-on/2-week-off treatment schedule. Placebo-assigned patients could cross over to sunitinib at disease progression/study unblinding. Overall survival (OS) was analyzed using conventional statistical methods and the rank-preserving structural failure time (RPSFT) method to explore cross-over impact. Circulating levels of angiogenesis biomarkers were analyzed. Results: In total, 243 patients were randomized to receive sunitinib and 118 to placebo, 103 of whom crossed over to open-label sunitinib. Conventional statistical analysis showed that OS converged in the sunitinib and placebo arms (median 72.7 vs. 64.9 weeks; HR, 0.876; P=0.306) as expected, given the cross-over design. RPSFT analysis estimated median OS for placebo of 39.0 weeks (HR, 0.505, 95% CI, 0.262-1.134; P = 0.306). No new safety concerns emerged with extended sunitinib treatment. No consistent associations were found between the pharmacodynamics of angiogenesis-related plasma proteins during sunitinib treatment and clinical outcome. Conclusions: The cross-over design provided evidence of sunitinib clinical benefit based on prolonged time to tumor progression during the double-blind phase of this trial. As expected, following cross-over, there was no statistical difference in OS. RPSFT analysis modeled the absence of cross-over, estimating a substantial sunitinib OS benefit relative to placebo. Long-term sunitinib treatment was tolerated without new adverse events.

UR - http://www.scopus.com/inward/record.url?scp=84861786753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861786753&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-3005

DO - 10.1158/1078-0432.CCR-11-3005

M3 - Article

C2 - 22661587

AN - SCOPUS:84861786753

VL - 18

SP - 3170

EP - 3179

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -